We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Did you mean alternative treatment
How investigators and sponsors should manage clinical trials during COVID-19
Get help to classify pharmaceutical products used to treat or prevent diseases or ailments (in humans or animals), including comparators used in clinical trials and placebos.
Information on herbal medicines, how to apply for a traditional herbal registration (THR), banned or restricted herbal ingredients, homeopathic medicines and fees.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
How to use a cost effectiveness analysis to evaluate your digital health product.
How to process manure, guano or digestive tract content for sale as a fertiliser in the EU, including how to propose a new treatment method.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report.
Find out about partial exemption and the methods and calculations to use to see how much input tax you can recover.
What best available techniques are, when you must follow them, how to propose alternatives and how to refer to them in your application.
Reported problems with the supply of an animal medicine and the date when the issue is expected to be resolved.
How to comply with the requirements on promoting medicines to the public and to prescribers and suppliers of medicines.
Collection of documents relating to COVID-19 treatments.
Read about talking therapies and counselling for mental health problems.
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
How the MHRA makes decisions on what is a medicinal product (borderline products).
How to get a marketing authorisation for an Advanced Therapy Medicinal Product (ATMP) so it can be sold and/or supplied in Great Britain.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.